01—Abstract
Summary
Summary of the 10-K filed March 11, 2005. Cited figures are marked; the original filing is the authoritative source.
Incyte Corporation's 10-K for fiscal 2004 describes a company focused on discovering and developing novel small molecule drugs for HIV, inflammatory disorders, cancer and diabetes, after shifting away from its genomic information products business.
Its lead candidate, Reverset, is in Phase IIb trials for HIV, with top-line interim results from about 140 patients suggesting sustained antiviral activity, though a higher than anticipated incidence of asymptomatic hyperlipasemia was observed in patients also receiving didanosine. The CCR2 receptor antagonist program completed a Phase I trial, and the sheddase inhibitor IND was filed in December 2004 with Phase I scheduled for March 2005. Financially, the company reported 2004 revenues of $14.1 milliona, down from $41.2 million in 2003, and a net loss of $164.8 million, or $2.21 per share.
Research and development expenses were $88.3 millionb and other expenses, mostly restructuring and impairment charges, were $54.2 million. Cash, cash equivalents and marketable securities rose to $469.8 million at year end, supported by a $250 million 3 1/2% convertible note issuance and an $83.3 million net common stock offering. Stockholders' equity fell to $78.5 million against $378.8 million of convertible subordinated debt, and the company stated that its existing resources should be adequate for at least the next twelve months.
The filing highlights ongoing risks, including the company's history of losses (an accumulated deficit of $736.3 millionc), its expectation of continued losses, its need for additional capital, its reliance on collaborators and contract research organizations, and the Invitrogen patent litigation, whose outcome cannot be reasonably estimated. The Iconix arbitration was settled in January 2005 with no material impact.
02—Key points
Key Highlights
- Lead drug candidate Reverset (an NRTI for HIV) is in Phase IIb trials; the interim analysis of about 140 patients suggested sustained antiviral activity, with the 16-week study expected to complete by June 2005.
- CCR2 receptor antagonist lead candidate completed a Phase I trial in 70 healthy volunteers; Phase IIa trials in rheumatoid arthritis and obese insulin-resistant patients are planned for the first half of 2005.
- Sheddase inhibitor IND was filed in December 2004, with Phase I clinical trials scheduled to begin in March 2005.
- 2004 revenues were $14.1 million, compared with $41.2 million in 2003, as the information products business declined and the Palo Alto facility was closed.
- Net loss was $164.8 million ($2.21 per share) in 2004, including $54.2 million of other expenses related to restructuring and impairment charges.
- Cash, cash equivalents and marketable securities were $469.8 million at December 31, 2004, versus $293.8 million a year earlier, after a $250 million convertible note issuance and an $83.3 million common stock offering.
- Convertible subordinated notes totaled $378.8 million and stockholders' equity was $78.5 million at year end, with an accumulated deficit of $736.3 million.
03—Questions
Frequently Asked Questions
What is Incyte's most advanced drug candidate and what did the interim data show?
Reverset, a once-daily nucleoside analog reverse transcriptase inhibitor for HIV, is in Phase IIb trials. Top-line interim results from about 140 patients suggested sustained antiviral activity in patients with multiple resistance mutations. The only adverse effect noted to date was a higher than anticipated incidence of asymptomatic hyperlipasemia in patients also receiving didanosine.
Why did revenues decline so sharply in 2004?
Revenues came from information products, which fell from $41.2 million in 2003 to $14.1 million in 2004. The filing attributes the decline to softening demand for genomic information, reduced research spending by pharmaceutical and biotechnology companies, and the February 2004 restructuring that closed the Palo Alto facility. The company expects information product revenues to remain substantially lower as it focuses on drug discovery.
How is Incyte funding its operations and is it adequately capitalized?
In 2004 Incyte issued $250 million of 3 1/2% convertible subordinated notes due 2011, with net proceeds of about $242.5 million, and completed a public offering of 9 million shares at $9.75 for net proceeds of $83.3 million. Cash, cash equivalents and marketable securities totaled $469.8 million at year end. The company believes these resources will be adequate for at least the next twelve months, but it expects continued losses and says it will need additional capital in the future.
What are the main legal and financial risks disclosed?
The company faces the Invitrogen patent infringement suit, filed in October 2001; the filing states that the possible range of loss cannot be reasonably estimated and that legal costs are expected regardless of outcome. Other risks include a history of operating losses with an accumulated deficit of $736.3 million, $378.8 million of convertible debt against $78.5 million of stockholders' equity, and dependence on collaborators such as Pharmasset for Reverset.
04—Continue